Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
Paolo Spagnolo, Oliver Distler, Christopher J. Ryerson, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 2, pp. 143-150
Open Access | Times Cited: 175

Showing 1-25 of 175 citing articles:

Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?
Meng Kou, Li Huang, Jinjuan Yang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 304
Mesenchymal stem cell-derived exosomes: Characteristics and applications in disease pathology and management
Hafiza Padinharayil, Jinsu Varghese, Cornelia M. Wilson, et al.
Life Sciences (2024) Vol. 342, pp. 122542-122542
Closed Access | Times Cited: 18
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Paolo Spagnolo, Christopher J. Ryerson, Rachel K. Putman, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 9, pp. 1065-1076
Closed Access | Times Cited: 94
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Gabrielle Y. Liu, G. R. Scott Budinger, Jane E. Dematte
BMJ (2022), pp. e066354-e066354
Open Access | Times Cited: 67
The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
Wen Zhu, Yehui Li, Junjie Zhao, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 541-552
Open Access | Times Cited: 55
Iguratimod ameliorates bleomycin-induced pulmonary fibrosis by inhibiting the EMT process and NLRP3 inflammasome activation
Wenping Liu, Xiao Han, Qing Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113460-113460
Open Access | Times Cited: 46
Immunomodulatory treatment of interstitial lung disease
L. van den Bosch, Fabrizio Luppi, Giovanni Ferrara, et al.
Therapeutic Advances in Respiratory Disease (2022) Vol. 16, pp. 175346662211170-175346662211170
Open Access | Times Cited: 39
Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers
Giuliana Cerro Chiang, Tanyalak Parimon
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2405-2405
Open Access | Times Cited: 31
Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Marya Ghazipura, Manoj J. Mammen, Brittany D. Bissell, et al.
Annals of the American Thoracic Society (2022) Vol. 19, Iss. 6, pp. 1030-1039
Closed Access | Times Cited: 37
Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Marya Ghazipura, Manoj J. Mammen, Derrick D. Herman, et al.
Annals of the American Thoracic Society (2022) Vol. 19, Iss. 6, pp. 1040-1049
Closed Access | Times Cited: 37
Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2
Samar A. Antar, Mohamed A. Saleh, Ahmed A. Al‐Karmalawy
Life Sciences (2022) Vol. 309, pp. 121048-121048
Open Access | Times Cited: 34
Coomassie brilliant blue G-250 dye attenuates bleomycin-induced lung fibrosis by regulating the NF-κB and NLRP3 crosstalk: A novel approach for filling an unmet medical need
Mona H. Zohny, Simona Cavalu, Mahmoud E. Youssef, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 148, pp. 112723-112723
Open Access | Times Cited: 30
The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study
Jiaqi Wang, Xiao Wang, Xiaoyan Qi, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 29
Resveratrol attenuates inflammation and fibrosis in rheumatoid arthritis-associated interstitial lung disease via the AKT/TMEM175 pathway
Nannan Liu, Xuefei Fan, Yubao Shao, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders
P. Panagopoulos, Andreas V. Goules, Anna‐Maria Hoffmann‐Vold, et al.
Therapeutic Advances in Musculoskeletal Disease (2021) Vol. 13
Open Access | Times Cited: 38
Glutamine Metabolism Is Required for Alveolar Regeneration during Lung Injury
Sisi Wang, Xue Li, Qingwen Ma, et al.
Biomolecules (2022) Vol. 12, Iss. 5, pp. 728-728
Open Access | Times Cited: 23
Senescence of alveolar epithelial cells impacts initiation and chronic phases of murine fibrosing interstitial lung disease
Zento Yamada, Junko Nishio, Kaori Motomura, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases
Yu‐Hsiang Chiu, Julia Spierings, Pim A. de Jong, et al.
Respiratory Medicine (2021) Vol. 187, pp. 106579-106579
Open Access | Times Cited: 31
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
Minrui Liang, Eric L. Matteson, Andy Abril, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 19
Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis
Mei Yang, Yanqing Wu, Xuemei Liu, et al.
Respiratory Medicine (2023) Vol. 216, pp. 107329-107329
Open Access | Times Cited: 12
The Role of Macrophages in Connective Tissue Disease-Associated Interstitial Lung Disease: Focusing on Molecular Mechanisms and Potential Treatment Strategies
Chia‐Chun Tseng, Ya-Wen Sung, Kuan‐Yu Chen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 11995-11995
Open Access | Times Cited: 12
Prevalence and mortality associations of interstitial lung abnormalities in rheumatoid arthritis within a multicentre prospective cohort of smokers
Gregory McDermott, Keigo Hayashi, Kazuki Yoshida, et al.
Lara D. Veeken (2023) Vol. 62, Iss. SI3, pp. SI286-SI295
Closed Access | Times Cited: 12
Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
Maria Boutel, Afroditi Boutou, Georgia Pitsiou, et al.
Diagnostics (2023) Vol. 13, Iss. 7, pp. 1221-1221
Open Access | Times Cited: 11
Leech extract alleviates idiopathic pulmonary fibrosis by TGF-β1/Smad3 signaling pathway
Yin Zhang, Yongbo Lu, Weijie Zhu, et al.
Journal of Ethnopharmacology (2024) Vol. 324, pp. 117737-117737
Closed Access | Times Cited: 4
Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study
Yusuke Ushio, Risa Wakiya, Tomohiro Kameda, et al.
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top